Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
222.08
-4.58 (-2.02%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Ascendis Pharma Analyst Ratings
Total Analysts
16
Consensus Rating
Strong Buy
Price Target
$281.50
Upside
+26.76%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Strong Buy Maintains $262 → $292 | Strong Buy | Maintains | $262 → $292 | +31.48% | Apr 16, 2026 |
| Wedbush | Wedbush | Buy Reiterates $273 | Buy | Reiterates | $273 | +22.93% | Apr 9, 2026 |
| Jefferies | Jefferies | Strong Buy Initiates $252 → $290 | Strong Buy | Initiates | $252 → $290 | +30.58% | Mar 16, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $250 → $275 | Buy | Maintains | $250 → $275 | +23.83% | Mar 3, 2026 |
| Oppenheimer | Oppenheimer | Buy Maintains $246 → $262 | Buy | Maintains | $246 → $262 | +17.98% | Feb 12, 2026 |
| Wedbush | Wedbush | Buy Maintains $240 → $273 | Buy | Maintains | $240 → $273 | +22.93% | Feb 12, 2026 |
| B of A Securities | B of A Securities | Strong Buy Maintains $246 → $260 | Strong Buy | Maintains | $246 → $260 | +17.07% | Jan 30, 2026 |
| Barclays | Barclays | Buy Initiates $342 | Buy | Initiates | $342 | +54.00% | Jan 28, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $245 → $250 | Buy | Maintains | $245 → $250 | +12.57% | Jan 20, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $322 → $330 | Buy | Maintains | $322 → $330 | +48.60% | Jan 20, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $297 → $322 | Buy | Maintains | $297 → $322 | +44.99% | Jan 9, 2026 |
| TD Cowen | TD Cowen | Strong Buy Reiterates $325 | Strong Buy | Reiterates | $325 | +46.34% | Jan 7, 2026 |
| Stifel | Stifel | Strong Buy Maintains $254 → $256 | Strong Buy | Maintains | $254 → $256 | +15.27% | Dec 11, 2025 |
| Wedbush | Wedbush | Buy Reiterates $220 | Buy | Reiterates | $220 | -0.94% | Nov 18, 2025 |
| Raymond James | Raymond James | Strong Buy Initiates $271 | Strong Buy | Initiates | $271 | +22.03% | Oct 17, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $203 → $254 | Buy | Maintains | $203 → $254 | +14.37% | Oct 13, 2025 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 10 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.